One-Stop shop: HIV prevention plus gender care shows promise

NCT ID NCT04742491

Completed Prevention Sponsor: HIV Prevention Trials Network Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether offering HIV prevention medication (PrEP) together with gender-affirming hormone therapy and peer support helps transgender women start and stick with PrEP. 304 participants were randomly assigned to get the combined services right away or after a 6-month delay. The goal was to see if this integrated approach is acceptable and feasible, and whether it improves PrEP use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Truvada or Descovy (HIV prevention medication)
What this could lead to: If successful, this approach could make it easier for transgender women to consistently use HIV prevention medication by addressing their broader health needs.
What could go wrong: This is a small, early-stage study focused on feasibility, not on proving HIV prevention. Results may not apply to all transgender women or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV PREVENTION

Contacts and locations

Locations

Bridge HIV CRS

San Francisco, California, 94102, United States
Harlem Prevention Center CRS

New York, New York, 10027, United States
Houston AIDS Research Team CRS

Houston, Texas, 77030, United States
Instituto de Pesquisa Clinicaq Evandro Chagas CRS

Manguinhos, Rio de Janeiro, 221045-900, Brazil
Penn Prevention CRS

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.